Biodexa Pharmaceuticals (BDRX) announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes. The study is an Investigator Initiated Trial conducted by the University of Alberta Diabetes Institute. The study will measure C-peptide levels and HbA1c after three months compared with baseline and the number of hyperglycemic events initially in 12 patients across three dose groups. The study may be expanded in due course.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa Pharmaceuticals Provides Shareholder Update and Advances eRapa Phase 3 Program
- Biodexa Pharmaceuticals sees cash runway into 1Q26
- Biodexa Pharmaceuticals Releases 2024 Annual Report and Announces AGM
- Biodexa Pharmaceuticals Plans Share Capital Reorganization and New Share Allotment
- Biodexa Pharmaceuticals Secures Additional $3M Grant for eRapa Phase 3 Program